Xeris Biopharma Holdings - Multiplikator EV/Sales XERS

Logo perusahaan publik Xeris Biopharma Holdings, Inc. (XERS)

Xeris Biopharma (XERS) is scaling its endocrinology portfolio to achieve stable cash flow, integrating ESG principles to reduce industrial waste. The company's current price-to-sales ratio reflects market expectations, where 8503.39 captures the current state of the parameter. Business development relies on the licensing of unique injection technologies and the co-creation of new drug formulations for the therapy of chronic pathologies.

Xeris Biopharma - Rasio nilai perusahaan marang pendapatan XERS (periode 23.11.2025 - 20.11.2026)

Rincian metrik keuangan lan pasar Xeris Biopharma (XERS)

- informasi babagan dhuwit lan arus kas:
Pambiji fundamental perusahaan:XERS, xerispharma.com
Produk seri Xeris Pharma

Professional managers utilize fundamental metrics to filter out overvalued assets. This indicator compares the market value of a business with its annual turnover, excluding the impact of debt load on the valuation. For Xeris Biopharma (XERS), this is critical, as geopolitical barriers limit revenue from international trials. The dynamics of the EV to total revenue multiple allow for the identification of the risk of overpaying for an asset. By analyzing this chart, an investor determines whether the business is in a stage of stagnation or overheating.